Myeloperoxidase: Expressing inflammation and oxidative stress in cardiovascular disease

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 115-138

  Anatoliotakis, Nikolaos ^a   Deftereos, Spyridon ^a   Bouras, Georgios ^a   Giannopoulos, Georgios ^a,b   Tsounis, Dimitrios ^a   Angelidis, Christos ^a   Kaoukis, Andreas ^a   Stefanadis, Christodoulos ^c  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cardiovascular disease; Endothelial damage; Free radicals; Inflammation; Inflammatory biomarkers; MPO H2O2 halide system; Myeloperoxidase; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; EOSINOPHIL PEROXIDASE; FREE RADICAL; HALIDE; HEMOPROTEIN; HYDROGEN PEROXIDE; LACTOPEROXIDASE; MICROBICIDE; MYELOPEROXIDASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

AEROBIC METABOLISM; ATHEROMATOSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ENDOTHELIUM INJURY; ENZYME KINETICS; ENZYME MECHANISM; GENETIC CODE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PEROXIDATION; PROGNOSIS; REVIEW; THROMBOSIS;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HALOGENS; HEART FAILURE; HUMANS; HYDROGEN PEROXIDE; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; OXIDATIVE STRESS; PEROXIDASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84877794345     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313020004     Document Type: Review

References (185)

1. van der Veen, B. S.; de Winther, M. P.; Heeringa, P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal, 2009, 11, 2899-2937.
2. Schultz, J. Myeloperoxidase. Ann N Y Acad Sci, 1958, 75, 22-30.
3. Koeffler, H. P.; Ranyard, J.; Pertcheck, M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood, 1985, 65, 484-491.
4. Klebanoff, S. J. Myeloperoxidase: friend and foe. J Leukoc Biol, 2005, 77, 598-625.
5. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol, 2005, 25, 1102-1111.
6. Eiserich, J. P.; Baldus, S.; Brennan, M. L.; Ma, W.; Zhang, C.; Tousson, A.; Castro, L.; Lusis, A. J.; Nauseef, W. M.; White, C. R.; Freeman, B. A. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science, 2002, 296, 2391-2394.
7. Fiedler, T. J.; Davey, C. A.; Fenna, R. E. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J Biol Chem, 2000, 275, 11964-11971.
8. Arnhold, J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc), 2004, 69, 4-9.
9. Lau, D.; Baldus, S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther, 2006, 111, 16-26.
10. Castellani, L. W.; Chang, J. J.; Wang, X.; Lusis, A. J.; Reynolds, W. F. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in 463G males. J Lipid Res, 2006, 47, 1366-1377.
11. Hoy, A.; Tregouet, D.; Leininger-Muller, B.; Poirier, O.; Maurice, M.; Sass, C.; Siest, G.; Tiret, L.; Visvikis, S. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet, 2001, 9, 780-786.
12. Naghavi, M.; Libby, P.; Falk, E.; Casscells, S. W.; Litovsky, S.; Rumberger, J.; Badimon, J. J.; Stefanadis, C.; Moreno, P.; Pasterkamp, G.; Fayad, Z.; Stone, P. H.; Waxman, S.; Raggi, P.; Madjid, M.; Zarrabi, A.; Burke, A.; Yuan, C.; Fitzgerald, P. J.; Siscovick, D. S.; de Korte, C. L.; Aikawa, M.; Juhani Airaksinen, K. E.; Assmann, G.; Becker, C. R.; Chesebro, J. H.; Farb, A.; Galis, Z. S.; Jackson, C.; Jang, I. K.; Koenig, W.; Lodder, R. A.; March, K.; Demirovic, J.; Navab, M.; Priori, S. G.; Rekhter, M. D.; Bahr, R.; Grundy, S. M.; Mehran, R.; Colombo, A.; Boerwinkle, E.; Ballantyne, C.; Insull, W., Jr.; Schwartz, R. S.; Vogel, R.; Serruys, P. W.; Hansson, G. K.; Faxon, D. P.; Kaul, S.; Drexler, H.; Greenland, P.; Muller, J. E.; Virmani, R.; Ridker, P. M.; Zipes, D. P.; Shah, P. K.; Willerson, J. T. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation, 2003, 108, 1664-1672.
13. Klebanoff, S. J. Iodination of bacteria: a bactericidal mechanism. J Exp Med, 1967, 126, 1063-1078.
14. Klebanoff, S. J. Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J Bacteriol, 1968, 95, 2131-2138.
15. Klebanoff, S. J. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science, 1970, 169, 1095-1097.
16. Klebanoff, S. J.; Hamon, C. B. Role of myeloperoxidase-mediated antimicrobial systems in intact leukocytes. J Reticuloendothel Soc, 1972, 12, 170-196.
17. Schultz, J.; Kaminker, K. Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch Biochem Biophys, 1962, 96, 465-467.
18. Hansson, M.; Olsson, I.; Nauseef, W. M. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys, 2006, 445, 214-224.
19. Malle, E.; Furtmuller, P. G.; Sattler, W.; Obinger, C. Myeloperoxidase: a target for new drug development? Br J Pharmacol, 2007, 152, 838-854.
20. Ballieux, B. E.; Zondervan, K. T.; Kievit, P.; Hagen, E. C.; van Es, L. A.; van der Woude, F. J.; Daha, M. R. Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC? Clin Exp Immunol, 1994, 97, 52-60.
21. Baldus, S.; Eiserich, J. P.; Mani, A.; Castro, L.; Figueroa, M.; Chumley, P.; Ma, W.; Tousson, A.; White, C. R.; Bullard, D. C.; Brennan, M. L.; Lusis, A. J.; Moore, K. P.; Freeman, B. A. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest, 2001, 108, 1759-1770.
22. Winterbourn, C. C. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta, 1985, 840, 204-210.
23. Thomas, E. L.; Jefferson, M. M.; Grisham, M. B. Myeloperoxidase-catalyzed incorporation of amines into proteins: role of hypochlorous acid and dichloramines. Biochemistry, 1982, 21, 6299-6308.
24. Carr, A. C.; McCall, M. R.; Frei, B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol, 2000, 20, 1716-1723.
25. Davies, M. J.; Hawkins, C. L.; Pattison, D. I.; Rees, M. D. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal, 2008, 10, 1199-1234.
26. Hazen, S. L.; Heinecke, J. W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest, 1997, 99, 2075-2081.
27. Hazen, S. L.; Hsu, F. F.; Mueller, D. M.; Crowley, J. R.; Heinecke, J. W. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest, 1996, 98, 1283-1289.
28. Buss, I. H.; Senthilmohan, R.; Darlow, B. A.; Mogridge, N.; Kettle, A. J.; Winterbourn, C. C. 3-Chlorotyrosine as a marker of protein damage by myeloperoxidase in tracheal aspirates from preterm infants: association with adverse respiratory outcome. Pediatr Res, 2003, 53, 455-462.
29. Kettle, A. J.; Chan, T.; Osberg, I.; Senthilmohan, R.; Chapman, A. L.; Mocatta, T. J.; Wagener, J. S. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med, 2004, 170, 1317-1323.
30. Gujral, J. S.; Liu, J.; Farhood, A.; Hinson, J. A.; Jaeschke, H. Functional importance of ICAM-1 in the mechanism of neutrophilinduced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol, 2004, 286, G499-507.
31. van der Vliet, A.; Eiserich, J. P.; Halliwell, B.; Cross, C. E. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem, 1997, 272, 7617-7625.
32. Malle, E.; Hazell, L.; Stocker, R.; Sattler, W.; Esterbauer, H.; Waeg, G. Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler Thromb Vasc Biol, 1995, 15, 982-989.
33. Pitt, A. R.; Spickett, C. M. Mass spectrometric analysis of HOCl- and free-radical-induced damage to lipids and proteins. Biochem Soc Trans, 2008, 36, 1077-1082.
34. Nahrendorf, M.; Sosnovik, D.; Chen, J. W.; Panizzi, P.; Figueiredo, J. L.; Aikawa, E.; Libby, P.; Swirski, F. K.; Weissleder, R. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemiareperfusion injury. Circulation, 2008, 117, 1153-1160.
35. Gross, S.; Gammon, S. T.; Moss, B. L.; Rauch, D.; Harding, J.; Heinecke, J. W.; Ratner, L.; Piwnica-Worms, D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med, 2009, 15, 455-461.
36. Franck, T.; Kohnen, S.; Deby-Dupont, G.; Grulke, S.; Deby, C.; Serteyn, D. A specific method for measurement of equine active myeloperoxidase in biological samples and in in vitro tests. J Vet Diagn Invest, 2006, 18, 326-334.
37. Shih, J.; Datwyler, S. A.; Hsu, S. C.; Matias, M. S.; Pacenti, D. P.; Lueders, C.; Mueller, C.; Danne, O.; Mockel, M. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem, 2008, 54, 1076-1079.
38. Hampton, M. B.; Kettle, A. J.; Winterbourn, C. C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood, 1998, 92, 3007-3017.
39. Gaut, J. P.; Byun, J.; Tran, H. D.; Lauber, W. M.; Carroll, J. A.; Hotchkiss, R. S.; Belaaouaj, A.; Heinecke, J. W. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest, 2002, 109, 1311-1319.
40. Amin, V. M.; Olson, N. F. Influence of catalase activity on resistance of coagulase-positive staphylococci to hydrogen peroxide. Appl Microbiol, 1968, 16, 267-270.
41. Kitahara, M.; Eyre, H. J.; Simonian, Y.; Atkin, C. L.; Hasstedt, S. J. Hereditary myeloperoxidase deficiency. Blood, 1981, 57, 888-893.
42. Stendahl, O.; Coble, B. I.; Dahlgren, C.; Hed, J.; Molin, L. Myeloperoxidase modulates the phagocytic activity of polymorphonuclear neutrophil leukocytes. Studies with cells from a myeloperoxidase-deficient patient. J Clin Invest, 1984, 73, 366-373.
43. Tiruppathi, C.; Naqvi, T.; Wu, Y.; Vogel, S. M.; Minshall, R. D.; Malik, A. B. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci U S A, 2004, 101, 7699-7704.
44. Lefkowitz, D. L.; Mills, K.; Morgan, D.; Lefkowitz, S. S. Macrophage activation and immunomodulation by myeloperoxidase. Proc Soc Exp Biol Med, 1992, 199, 204-210.
45. Lefkowitz, D. L.; Mills, K. C.; Moguilevsky, N.; Bollen, A.; Vaz, A.; Lefkowitz, S. S. Regulation of macrophage function by human recombinant myeloperoxidase. Immunol Lett, 1993, 36, 43-49.
46. Hunninghake, G. W.; Gadek, J. E.; Kawanami, O.; Ferrans, V. J.; Crystal, R. G. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol, 1979, 97, 149-206.
47. Spencer, J. P.; Whiteman, M.; Jenner, A.; Halliwell, B. Nitriteinduced deamination and hypochlorite-induced oxidation of DNA in intact human respiratory tract epithelial cells. Free Radic Biol Med, 2000, 28, 1039-1050.
48. Johnson, R. J.; Guggenheim, S. J.; Klebanoff, S. J.; Ochi, R. F.; Wass, A.; Baker, P.; Schulze, M.; Couser, W. G. Morphologic correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of the neutrophil. Lab Invest, 1988, 58, 294-301.
49. Johnson, K. J.; Fantone, J. C., 3rd; Kaplan, J.; Ward, P. A. In vivo damage of rat lungs by oxygen metabolites. J Clin Invest, 1981, 67, 983-993.
50. Kutter, D.; Devaquet, P.; Vanderstocken, G.; Paulus, J. M.; Marchal, V.; Gothot, A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol, 2000, 104, 10-15.
51. Nikpoor, B.; Turecki, G.; Fournier, C.; Theroux, P.; Rouleau, G. A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J, 2001, 142, 336-339.
52. Pecoits-Filho, R.; Stenvinkel, P.; Marchlewska, A.; Heimburger, O.; Barany, P.; Hoff, C. M.; Holmes, C. J.; Suliman, M.; Lindholm, B.; Schalling, M.; Nordfors, L. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl, 2003, S172-176.
53. Zheng, L.; Nukuna, B.; Brennan, M. L.; Sun, M.; Goormastic, M.; Settle, M.; Schmitt, D.; Fu, X.; Thomson, L.; Fox, P. L.; Ischiropoulos, H.; Smith, J. D.; Kinter, M.; Hazen, S. L. Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 2004, 114, 529-541.
54. Pennathur, S.; Bergt, C.; Shao, B.; Byun, J.; Kassim, S. Y.; Singh, P.; Green, P. S.; McDonald, T. O.; Brunzell, J.; Chait, A.; Oram, J. F.; O'Brien, K.; Geary, R. L.; Heinecke, J. W. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem, 2004, 279, 42977-42983.
55. Bergt, C.; Pennathur, S.; Fu, X.; Byun, J.; O'Brien, K.; McDonald, T. O.; Singh, P.; Anantharamaiah, G. M.; Chait, A.; Brunzell, J.; Geary, R. L.; Oram, J. F.; Heinecke, J. W. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A, 2004, 101, 13032-13037.
56. Mocatta, T. J.; Pilbrow, A. P.; Cameron, V. A.; Senthilmohan, R.; Frampton, C. M.; Richards, A. M.; Winterbourn, C. C. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol, 2007, 49, 1993-2000.
57. Tsimikas, S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol, 2006, 98, 9P-17P.
58. Shishehbor, M. H.; Brennan, M. L.; Aviles, R. J.; Fu, X.; Penn, M. S.; Sprecher, D. L.; Hazen, S. L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation, 2003, 108, 426-431.
59. Kumar, A. P.; Reynolds, W. F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun, 2005, 331, 442-451.
60. Mathew, M.; Tay, E.; Cusi, K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol, 2010, 9, 9.
61. Autenrieth, C. S.; Emeny, R. T.; Herder, C.; Doring, A.; Peters, A.; Koenig, W.; Thorand, B. Myeloperoxidase, but not oxidized LDL, is associated with leisure-time physical activity: results from the MONICA/KORA Augsburg Studies 1984-1995. Atherosclerosis, 2011, 219, 774-777.
62. Rana, J. S.; Arsenault, B. J.; Despres, J. P.; Cote, M.; Talmud, P. J.; Ninio, E.; Wouter Jukema, J.; Wareham, N. J.; Kastelein, J. J.; Khaw, K. T.; Boekholdt, S. M. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J, 2011, 32, 336-344.
63. Mertens, A.; Holvoet, P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J, 2001, 15, 2073-2084.
64. Daugherty, A.; Dunn, J. L.; Rateri, D. L.; Heinecke, J. W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest, 1994, 94, 437-444.
65. Sugiyama, S.; Okada, Y.; Sukhova, G. K.; Virmani, R.; Heinecke, J. W.; Libby, P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol, 2001, 158, 879-891.
66. Kirk, E. A.; Dinauer, M. C.; Rosen, H.; Chait, A.; Heinecke, J. W.; LeBoeuf, R. C. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol, 2000, 20, 1529-1535.
67. Brennan, M. L.; Anderson, M. M.; Shih, D. M.; Qu, X. D.; Wang, X.; Mehta, A. C.; Lim, L. L.; Shi, W.; Hazen, S. L.; Jacob, J. S.; Crowley, J. R.; Heinecke, J. W.; Lusis, A. J. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest, 2001, 107, 419-430.
68. Jandl, R. C.; Andre-Schwartz, J.; Borges-DuBois, L.; Kipnes, R. S.; McMurrich, B. J.; Babior, B. M. Termination of the respiratory burst in human neutrophils. J Clin Invest, 1978, 61, 1176-1185.
69. Askari, A. T.; Brennan, M. L.; Zhou, X.; Drinko, J.; Morehead, A.; Thomas, J. D.; Topol, E. J.; Hazen, S. L.; Penn, M. S. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med, 2003, 197, 615-624.
70. Podrez, E. A.; Schmitt, D.; Hoff, H. F.; Hazen, S. L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest, 1999, 103, 1547-1560.
71. Zhang, R.; Brennan, M. L.; Shen, Z.; MacPherson, J. C.; Schmitt, D.; Molenda, C. E.; Hazen, S. L. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem, 2002, 277, 46116-46122.
72. Baldus, S.; Heitzer, T.; Eiserich, J. P.; Lau, D.; Mollnau, H.; Ortak, M.; Petri, S.; Goldmann, B.; Duchstein, H. J.; Berger, J.; Helmchen, U.; Freeman, B. A.; Meinertz, T.; Munzel, T. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med, 2004, 37, 902-911.
73. Roman, R. M.; Wendland, A. E.; Polanczyk, C. A. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Arq Bras Cardiol, 2008, 91, e11-19.
74. Vasilyev, N.; Williams, T.; Brennan, M. L.; Unzek, S.; Zhou, X.; Heinecke, J. W.; Spitz, D. R.; Topol, E. J.; Hazen, S. L.; Penn, M. S. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation, 2005, 112, 2812-2820.
75. Ford, D. A. Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia. Clin Lipidol, 2010, 5, 835-852.
76. Desrochers, P. E.; Weiss, S. J. Proteolytic inactivation of alpha-1- proteinase inhibitor by a neutrophil metalloproteinase. J Clin Invest, 1988, 81, 1646-1650.
77. Heller, J. I.; Crowley, J. R.; Hazen, S. L.; Salvay, D. M.; Wagner, P.; Pennathur, S.; Heinecke, J. W. p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J Biol Chem, 2000, 275, 9957-9962.
78. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res, 2009, 50 Suppl, S346-351.
79. Shao, B.; Oda, M. N.; Oram, J. F.; Heinecke, J. W. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol, 2010, 23, 447-454.
80. Feng, H.; Li, X. A. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes, 2009, 16, 156-162.
81. Shao, B.; Bergt, C.; Fu, X.; Green, P.; Voss, J. C.; Oda, M. N.; Oram, J. F.; Heinecke, J. W. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem, 2005, 280, 5983-5993.
82. Smith, J. D. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol, 2010, 4, 382-388.
83. Peng, D. Q.; Brubaker, G.; Wu, Z.; Zheng, L.; Willard, B.; Kinter, M.; Hazen, S. L.; Smith, J. D. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc Biol, 2008, 28, 2063-2070.
84. Sirpal, S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci (Lond), 2009, 116, 681-695.
85. Sugiyama, S.; Kugiyama, K.; Aikawa, M.; Nakamura, S.; Ogawa, H.; Libby, P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol, 2004, 24, 1309-1314.
86. Hazen, S. L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol, 2004, 24, 1143-1146.
87. Naruko, T.; Ueda, M.; Haze, K.; van der Wal, A. C.; van der Loos, C. M.; Itoh, A.; Komatsu, R.; Ikura, Y.; Ogami, M.; Shimada, Y.; Ehara, S.; Yoshiyama, M.; Takeuchi, K.; Yoshikawa, J.; Becker, A. E. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation, 2002, 106, 2894-2900.
88. Maugeri, N.; Rovere-Querini, P.; Evangelista, V.; Godino, C.; Demetrio, M.; Baldini, M.; Figini, F.; Coppi, G.; Slavich, M.; Camera, M.; Bartorelli, A.; Marenzi, G.; Campana, L.; Baldissera, E.; Sabbadini, M. G.; Cianflone, D.; Tremoli, E.; D'Angelo, A.; Manfredi, A. A.; Maseri, A. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS One, 2012, 7, e39484.
89. Buffon, A.; Biasucci, L. M.; Liuzzo, G.; D'Onofrio, G.; Crea, F.; Maseri, A. Widespread coronary inflammation in unstable angina. N Engl J Med, 2002, 347, 5-12.
90. Marshall, C. J.; Nallaratnam, M.; Mocatta, T.; Smyth, D.; Richards, M.; Elliott, J. M.; Blake, J.; Winterbourn, C. C.; Kettle, A. J.; McClean, D. R. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Am J Cardiol, 2010, 106, 316-322.
91. Biasucci, L. M.; D'Onofrio, G.; Liuzzo, G.; Zini, G.; Monaco, C.; Caligiuri, G.; Tommasi, M.; Rebuzzi, A. G.; Maseri, A. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol, 1996, 27, 611-616.
92. Schindhelm, R. K.; van der Zwan, L. P.; Teerlink, T.; Scheffer, P. G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem, 2009, 55, 1462-1470.
93. Gach, O.; Biemar, C.; Nys, M.; Deby-Dupont, G.; Chapelle, J. P.; Deby, C.; Lamy, M.; Pierard, L. A.; Legrand, V. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron Artery Dis, 2005, 16, 59-65.
94. Baldus, S.; Heeschen, C.; Meinertz, T.; Zeiher, A. M.; Eiserich, J. P.; Munzel, T.; Simoons, M. L.; Hamm, C. W. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003, 108, 1440-1445.
95. Zhang, R.; Brennan, M. L.; Fu, X.; Aviles, R. J.; Pearce, G. L.; Penn, M. S.; Topol, E. J.; Sprecher, D. L.; Hazen, S. L. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA, 2001, 286, 2136-2142.
96. Brennan, M. L.; Penn, M. S.; Van Lente, F.; Nambi, V.; Shishehbor, M. H.; Aviles, R. J.; Goormastic, M.; Pepoy, M. L.; McErlean, E. S.; Topol, E. J.; Nissen, S. E.; Hazen, S. L. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med, 2003, 349, 1595-1604.
97. Khan, S. Q.; Kelly, D.; Quinn, P.; Davies, J. E.; Ng, L. L. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart, 2007, 93, 826-831.
98. Cavusoglu, E.; Ruwende, C.; Eng, C.; Chopra, V.; Yanamadala, S.; Clark, L. T.; Pinsky, D. J.; Marmur, J. D. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol, 2007, 99, 1364-1368.
99. Duzguncinar, O.; Yavuz, B.; Hazirolan, T.; Deniz, A.; Tokgozoglu, S. L.; Akata, D.; Demirpence, E. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol, 2008, 63, 147-152.
100. Meuwese, M. C.; Stroes, E. S.; Hazen, S. L.; van Miert, J. N.; Kuivenhoven, J. A.; Schaub, R. G.; Wareham, N. J.; Luben, R.; Kastelein, J. J.; Khaw, K. T.; Boekholdt, S. M. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007, 50, 159-165.
101. Meuwese, M. C.; Trip, M. D.; van Wissen, S.; van Miert, J. N.; Kastelein, J. J.; Stroes, E. S. Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis, 2008, 197, 916-921.
102. Wiersma, J. J.; Verberne, H. J.; Meuwese, M. C.; Stroes, E. S.; van Miert, J. N.; van Eck-Smit, B. L.; Tijssen, J. G.; Piek, J. J.; Trip, M. D. Myeloperoxidase is not associated with scintigraphic myocardial perfusion abnormalities in type 2 diabetic patients with mild stable anginal complaints. Clin Chim Acta, 2011, 412, 86-90.
103. Esporcatte, R.; Rey, H. C.; Rangel, F. O.; Rocha, R. M.; Mendonca Filho, H. T.; Dohmann, H. F.; Albanesi Filho, F. M. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol, 2007, 89, 377-384.
104. Khan, D. A.; Sharif, M. S.; Khan, F. A. Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancyassociated plasma protein A assays for triage of patients with acute myocardial infarction. Korean J Lab Med, 2011, 31, 172-178.
105. Nicholls, S. J.; Tang, W. H.; Brennan, D.; Brennan, M. L.; Mann, S.; Nissen, S. E.; Hazen, S. L. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem, 2011, 57, 1762-1770.
106. Rudolph, V.; Keller, T.; Schulz, A.; Ojeda, F.; Rudolph, T. K.; Tzikas, S.; Bickel, C.; Meinertz, T.; Munzel, T.; Blankenberg, S.; Baldus, S. Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circ Cardiovasc Genet, 2012, 5, 561-568.
107. Li, S. H.; Xing, Y. W.; Li, Z. Z.; Bai, S. G.; Wang, J. [Clinical implications of relationship between myeloperoxidase and acute coronary syndromes]. Zhonghua Xin Xue Guan Bing Za Zhi, 2007, 35, 241-244.
108. Ndrepepa, G.; Braun, S.; Mehilli, J.; von Beckerath, N.; Schomig, A.; Kastrati, A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest, 2008, 38, 90-96.
109. Morrow, D. A.; Sabatine, M. S.; Brennan, M. L.; de Lemos, J. A.; Murphy, S. A.; Ruff, C. T.; Rifai, N.; Cannon, C. P.; Hazen, S. L. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J, 2008, 29, 1096-1102.
110. Dominguez-Rodriguez, A.; Samimi-Fard, S.; Abreu-Gonzalez, P.; Garcia-Gonzalez, M. J.; Kaski, J. C. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol, 2008, 101, 1537-1540.
111. Cheng, M. L.; Chen, C. M.; Gu, P. W.; Ho, H. Y.; Chiu, D. T. Elevated levels of myeloperoxidase, white blood cell count and 3-chlorotyrosine in Taiwanese patients with acute myocardial infarction. Clin Biochem, 2008, 41, 554-560.
112. Samimi-Fard, S.; Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Enjuanes-Grau, C.; Blanco-Palacios, G.; Hernandez-Baldomero, I. F.; Bosa-Ojeda, F.; Marrero-Rodriguez, F. Role of myeloperoxidase as predictor of systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol, 2009, 104, 634-637.
113. Lobbes, M. B.; Kooi, M. E.; Lutgens, E.; Ruiters, A. W.; Lima Passos, V.; Braat, S. H.; Rousch, M.; Ten Cate, H.; van Engelshoven, J. M.; Daemen, M. J.; Heeneman, S. Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multibiomarker approach. Int J Vasc Med, 2010, 2010, 726207.
114. Liu, C.; Xie, G.; Huang, W.; Yang, Y.; Li, P.; Tu, Z. Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients. J Atheroscler Thromb, 2012, 19, 435-443.
115. Tang, W. H.; Wu, Y.; Nicholls, S. J.; Hazen, S. L. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem, 2011, 57, 33-39.
116. Wong, N. D.; Gransar, H.; Narula, J.; Shaw, L.; Moon, J. H.; Miranda-Peats, R.; Rozanski, A.; Hayes, S. W.; Thomson, L. E.; Friedman, J. D.; Berman, D. S. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging, 2009, 2, 1093-1099.
117. Kaya, M. G.; Yalcin, R.; Okyay, K.; Poyraz, F.; Bayraktar, N.; Pasaoglu, H.; Boyaci, B.; Cengel, A. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J, 2012, 39, 500-506.
118. Kalantar-Zadeh, K.; Brennan, M. L.; Hazen, S. L. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis, 2006, 48, 59-68.
119. Stefanescu, A.; Braun, S.; Ndrepepa, G.; Koppara, T.; Pavaci, H.; Mehilli, J.; Schomig, A.; Kastrati, A. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J, 2008, 155, 356-360.
120. El-Bejjani, D.; Hazen, S. L.; Mackay, W.; Glass, N. E.; Hulgan, T.; Tungsiripat, M.; McComsey, G. A. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials, 2008, 9, 207-211.
121. Kubala, L.; Lu, G.; Baldus, S.; Berglund, L.; Eiserich, J. P. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta, 2008, 394, 59-62.
122. Apple, F. S.; Pearce, L. A.; Chung, A.; Ler, R.; Murakami, M. M. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem, 2007, 53, 874-881.
123. Scirica, B. M.; Sabatine, M. S.; Jarolim, P.; Murphy, S. A.; de Lemos, J. L.; Braunwald, E.; Morrow, D. A. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J, 2011, 32, 697-705.
124. Mitchell, A. M.; Garvey, J. L.; Kline, J. A. Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad Emerg Med, 2006, 13, 803-806.
125. Anker, S. D.; von Haehling, S. Inflammatory mediators in chronic heart failure: an overview. Heart, 2004, 90, 464-470.
126. Eleuteri, E.; Di Stefano, A.; Ricciardolo, F. L.; Magno, F.; Gnemmi, I.; Colombo, M.; Anzalone, R.; Cappello, F.; La Rocca, G.; Tarro Genta, F.; Zummo, G.; Giannuzzi, P. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol, 2009, 135, 386-390.
127. La Rocca, G.; Di Stefano, A.; Eleuteri, E.; Anzalone, R.; Magno, F.; Corrao, S.; Loria, T.; Martorana, A.; Di Gangi, C.; Colombo, M.; Sansone, F.; Patane, F.; Farina, F.; Rinaldi, M.; Cappello, F.; Giannuzzi, P.; Zummo, G. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Res Cardiol, 2009, 104, 307-320.
128. Cameron, V. A.; Mocatta, T. J.; Pilbrow, A. P.; Frampton, C. M.; Troughton, R. W.; Richards, A. M.; Winterbourn, C. C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension, 2006, 47, 1155-1161.
129. Reichlin, T.; Socrates, T.; Egli, P.; Potocki, M.; Breidthardt, T.; Arenja, N.; Meissner, J.; Noveanu, M.; Reiter, M.; Twerenbold, R.; Schaub, N.; Buser, A.; Mueller, C. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem, 2010, 56, 944-951.
130. Tang, W. H.; Brennan, M. L.; Philip, K.; Tong, W.; Mann, S.; Van Lente, F.; Hazen, S. L. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol, 2006, 98, 796-799.
131. Tang, W. H.; Katz, R.; Brennan, M. L.; Aviles, R. J.; Tracy, R. P.; Psaty, B. M.; Hazen, S. L. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol, 2009, 103, 1269-1274.
132. Ng, L. L.; Pathik, B.; Loke, I. W.; Squire, I. B.; Davies, J. E. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J, 2006, 152, 94-101.
133. Rudolph, V.; Rudolph, T. K.; Hennings, J. C.; Blankenberg, S.; Schnabel, R.; Steven, D.; Haddad, M.; Knittel, K.; Wende, S.; Wenzel, J.; Munzel, T.; Heitzer, T.; Meinertz, T.; Hubner, C.; Baldus, S. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med, 2007, 43, 1189-1196.
134. Rudolph, V.; Rudolph, T. K.; Kubala, L.; Clauberg, N.; Maas, R.; Pekarova, M.; Klinke, A.; Lau, D.; Szocs, K.; Meinertz, T.; Boger, R. H.; Baldus, S. A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. Free Radic Biol Med, 2009, 47, 1584-1590.
135. Michowitz, Y.; Kisil, S.; Guzner-Gur, H.; Rubinstein, A.; Wexler, D.; Sheps, D.; Keren, G.; George, J. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J, 2008, 10, 884-888.
136. Tang, W. H.; Tong, W.; Troughton, R. W.; Martin, M. G.; Shrestha, K.; Borowski, A.; Jasper, S.; Hazen, S. L.; Klein, A. L. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol, 2007, 49, 2364-2370.
137. Shah, K. B.; Kop, W. J.; Christenson, R. H.; Diercks, D. B.; Kuo, D.; Henderson, S.; Hanson, K.; Mehra, M. R.; deFilippi, C. R. Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem, 2009, 55, 59-67.
138. Li, J. J.; Fang, C. H.; Hui, R. T. Is hypertension an inflammatory disease? Med Hypotheses, 2005, 64, 236-240.
139. Van der Zwan, L. P.; Scheffer, P. G.; Dekker, J. M.; Stehouwer, C. D.; Heine, R. J.; Teerlink, T. Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension, 2010, 55, 1366-1372.
140. Haslacher, H.; Perkmann, T.; Gruenewald, J.; Exner, M.; Endler, G.; Scheichenberger, V.; Wagner, O.; Schillinger, M. Plasma myeloperoxidase level and peripheral arterial disease. Eur J Clin Invest, 2012, 42, 463-469.
141. Ali, Z.; Sarcia, P.; Mosley, T. H., Jr.; Kondragunta, V.; Kullo, I. J. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med, 2009, 14, 215-220.
142. Brevetti, G.; Schiano, V.; Laurenzano, E.; Giugliano, G.; Petretta, M.; Scopacasa, F.; Chiariello, M. Myeloperoxidase, but not Creactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J, 2008, 29, 224-230.
143. Exner, M.; Minar, E.; Mlekusch, W.; Sabeti, S.; Amighi, J.; Lalouschek, W.; Maurer, G.; Bieglmayer, C.; Kieweg, H.; Wagner, O.; Schillinger, M. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol, 2006, 47, 2212-2218.
144. Murabito, J. M.; Keyes, M. J.; Guo, C. Y.; Keaney, J. F., Jr.; Vasan, R. S.; D'Agostino, R. B., Sr.; Benjamin, E. J. Crosssectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis, 2009, 203, 509-514.
145. Issac, T. T.; Dokainish, H.; Lakkis, N. M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol, 2007, 50, 2021-2028.
146. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol, 2012, 60, 1790-1796.
147. Carnes, C. A.; Chung, M. K.; Nakayama, T.; Nakayama, H.; Baliga, R. S.; Piao, S.; Kanderian, A.; Pavia, S.; Hamlin, R. L.; McCarthy, P. M.; Bauer, J. A.; Van Wagoner, D. R. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res, 2001, 89, E32-38.
148. Xu, J.; Cui, G.; Esmailian, F.; Plunkett, M.; Marelli, D.; Ardehali, A.; Odim, J.; Laks, H.; Sen, L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation, 2004, 109, 363-368.
149. Rudolph, V.; Andrie, R. P.; Rudolph, T. K.; Friedrichs, K.; Klinke, A.; Hirsch-Hoffmann, B.; Schwoerer, A. P.; Lau, D.; Fu, X.; Klingel, K.; Sydow, K.; Didie, M.; Seniuk, A.; von Leitner, E. C.; Szoecs, K.; Schrickel, J. W.; Treede, H.; Wenzel, U.; Lewalter, T.; Nickenig, G.; Zimmermann, W. H.; Meinertz, T.; Boger, R. H.; Reichenspurner, H.; Freeman, B. A.; Eschenhagen, T.; Ehmke, H.; Hazen, S. L.; Willems, S.; Baldus, S. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med, 2010, 16, 470-474.
150. Fu, X.; Kassim, S. Y.; Parks, W. C.; Heinecke, J. W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem, 2003, 278, 28403-28409.
151. Friedrichs, K.; Baldus, S.; Klinke, A. Fibrosis in Atrial Fibrillation - Role of Reactive Species and MPO. Front Physiol, 2012, 3, 214.
152. Aviles, R. J.; Martin, D. O.; Apperson-Hansen, C.; Houghtaling, P. L.; Rautaharju, P.; Kronmal, R. A.; Tracy, R. P.; Van Wagoner, D. R.; Psaty, B. M.; Lauer, M. S.; Chung, M. K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108, 3006-3010.
153. Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M. A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96, 1180-1184.
154. Fontes, M. L.; Mathew, J. P.; Rinder, H. M.; Zelterman, D.; Smith, B. R.; Rinder, C. S. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg, 2005, 101, 17-23, table of contents.
155. Schnabel, R. B.; Larson, M. G.; Yamamoto, J. F.; Kathiresan, S.; Rong, J.; Levy, D.; Keaney, J. F., Jr.; Wang, T. J.; Vasan, R. S.; Benjamin, E. J. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol, 2009, 104, 92-96.
156. Richter, B.; Gwechenberger, M.; Socas, A.; Zorn, G.; Albinni, S.; Marx, M.; Bergler-Klein, J.; Binder, T.; Wojta, J.; Gossinger, H. D. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol, 2012, 101, 217-225.
157. Lin, C. S.; Pan, C. H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci, 2008, 65, 1489-1508.
158. Casaclang-Verzosa, G.; Gersh, B. J.; Tsang, T. S. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol, 2008, 51, 1-11.
159. Frankwich, K.; Tibble, C.; Torres-Gonzalez, M.; Bonner, M.; Lefkowitz, R.; Tyndall, M.; Schmid-Schonbein, G. W.; Villarreal, F.; Heller, M.; Herbst, K. Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond), 2012, 9, 35.
160. Zhi, W.; Sharma, A.; Purohit, S.; Miller, E.; Bode, B.; Anderson, S. W.; Reed, J. C.; Steed, R. D.; Steed, L.; Hopkins, D.; She, J. X. Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays. Mol Cell Proteomics, 2011, 10, M111 012203.
161. Jornayvaz, F. R.; Brulhart-Meynet, M. C.; James, R. W. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis, 2009, 19, 613-619.
162. Wiersma, J. J.; Meuwese, M. C.; van Miert, J. N.; Kastelein, A.; Tijssen, J. G.; Piek, J. J.; Trip, M. D. Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med Sci Monit, 2008, 14, CR406-410.
163. Moldoveanu, E.; Tanaseanu, C.; Tanaseanu, S.; Kosaka, T.; Manea, G.; Marta, D. S.; Popescu, L. M. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med, 2006, 17, 38-42.
164. Zhang, C.; Yang, J.; Jennings, L. K. Leukocyte-derived myeloperoxidase amplifies high-glucose--induced endothelial dysfunction through interaction with high-glucose--stimulated, vascular non--leukocyte-derived reactive oxygen species. Diabetes, 2004, 53, 2950-2959.
165. Albayrak, A.; Uyanik, M. H.; Odabasoglu, F.; Halici, Z.; Uyanik, A.; Bayir, Y.; Albayrak, F.; Albayrak, Y.; Polat, B.; Suleyman, H. The effects of diabetes and/or polymicrobial sepsis on the status of antioxidant enzymes and pro-inflammatory cytokines on heart, liver, and lung of ovariectomized rats. J Surg Res, 2011, 169, 67-75.
166. Bobbert, P.; Rauch, U.; Stratmann, B.; Goldin-Lang, P.; Antoniak, S.; Bobbert, T.; Schultheiss, H. P.; Tschoepe, D. High molecular weight adiponectin correlates positively with myeloperoxidase in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract, 2008, 82, 179-184.
167. Kunitomo, M.; Yamaguchi, Y.; Kagota, S.; Otsubo, K. Beneficial effect of coenzyme Q10 on increased oxidative and nitrative stress and inflammation and individual metabolic components developing in a rat model of metabolic syndrome. J Pharmacol Sci, 2008, 107, 128-137.
168. Rector, R. S.; Warner, S. O.; Liu, Y.; Hinton, P. S.; Sun, G. Y.; Cox, R. H.; Stump, C. S.; Laughlin, M. H.; Dellsperger, K. C.; Thomas, T. R. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab, 2007, 293, E500-506.
169. Nosaka, M.; Ishida, Y.; Kimura, A.; Kondo, T. Time-dependent appearance of intrathrombus neutrophils and macrophages in a stasis-induced deep vein thrombosis model and its application to thrombus age determination. Int J Legal Med, 2009, 123, 235-240.
170. Downing, L. J.; Strieter, R. M.; Kadell, A. M.; Wilke, C. A.; Brown, S. L.; Wrobleski, S. K.; Burdick, M. D.; Hulin, M. S.; Fowlkes, J. B.; Greenfield, L. J.; Wakefield, T. W. Neutrophils are the initial cell type identified in deep venous thrombosis induced vein wall inflammation. ASAIO J, 1996, 42, M677-682.
171. Mitchell, A. M.; Nordenholz, K. E.; Kline, J. A. Tandem measurement of D-dimer and myeloperoxidase or C-reactive protein to effectively screen for pulmonary embolism in the emergency department. Acad Emerg Med, 2008, 15, 800-805.
172. Baldus, S.; Rudolph, V.; Roiss, M.; Ito, W. D.; Rudolph, T. K.; Eiserich, J. P.; Sydow, K.; Lau, D.; Szocs, K.; Klinke, A.; Kubala, L.; Berglund, L.; Schrepfer, S.; Deuse, T.; Haddad, M.; Risius, T.; Klemm, H.; Reichenspurner, H. C.; Meinertz, T.; Heitzer, T. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation, 2006, 113, 1871-1878.
173. Ndrepepa, G.; Braun, S.; Schomig, A.; Kastrati, A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol, 2011, 100, 327-333.
174. Beril Gok, H.; Solaroglu, I.; Okutan, O.; Cimen, B.; Kaptanoglu, E.; Palaoglu, S. Metoprolol treatment decreases tissue myeloperoxidase activity after spinal cord injury in rats. J Clin Neurosci, 2007, 14, 138-142.
175. Gao, F.; Chen, J.; Lopez, B. L.; Christopher, T. A.; Gu, J.; Lysko, P.; Ruffolo, R. R., Jr.; Ohlstein, E. H.; Ma, X. L.; Yue, T. L. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol, 2000, 406, 109-116.
176. Macickova, T.; Pecivova, J.; Nosal, R.; Lojek, A.; Pekarova, M.; Cupanikova, D. Inhibition of superoxide generation and myeloperoxidase release by carvedilol after receptor and nonreceptor stimulation of human neutrophils. Neuro Endocrinol Lett, 2008, 29, 790-793.
177. Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis, 2010, 210, 194-198.
178. Zhou, T.; Zhou, S. H.; Qi, S. S.; Shen, X. Q.; Zeng, G. F.; Zhou, H. N. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta, 2006, 368, 168-172.
179. Stenvinkel, P.; Rodriguez-Ayala, E.; Massy, Z. A.; Qureshi, A. R.; Barany, P.; Fellstrom, B.; Heimburger, O.; Lindholm, B.; Alvestrand, A. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol, 2006, 1, 281-287.
180. Chen, J.; Shen, H.; Nagasawa, Y.; Mitsui, K.; Tsurugi, K.; Hashimoto, K. Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats. J Pharmacol Sci, 2007, 103, 317-322.
181. Davignon, J.; Jacob, R. F.; Mason, R. P. The antioxidant effects of statins. Coron Artery Dis, 2004, 15, 251-258.
182. Van Antwerpen, P.; Boudjeltia, K. Z.; Vaes, M.; Babar, S.; Madhoun, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Neve, J.; Ducobu, J. The pleiotropic effect of statins in haemodialysis patients is not the consequence of an inhibition of LDL oxidation by myeloperoxidase. Nephrol Dial Transplant, 2006, 21, 2672-2674.
183. de Gusmao, F. M.; Becker, C.; Carvalho, M. H.; Barros, L. F. Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction. Int J Cardiol, 2005, 100, 363-370.
184. Liu, H. R.; Tao, L.; Gao, E.; Qu, Y.; Lau, W. B.; Lopez, B. L.; Christopher, T. A.; Koch, W.; Yue, T. L.; Ma, X. L. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res, 2009, 81, 344-352.
185. Dolezalova, R.; Haluzik, M. M.; Bosanska, L.; Lacinova, Z.; Kasalova, Z.; Stulc, T.; Haluzik, M. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res, 2007, 56, 741-748.